Clinuvel Pharmaceuticals Limited (ASX: CUV) - ETF Exposure

Current share price for CUV : $9.440 0.07 (0.75%)⁺

CLINUVEL (CUV) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialised populations. As pioneers in photo medicine and the family of melanocortin peptides

CUV General Information ⁺

ASX Code	CUV
Website	N/A
Industry/Sector	Biotechnology
Market Cap ($M)	476
CUV Share Price	$9.440
Day High	$9.500
Day Low	$9.200
Last Close	$9.440
CUV Share Price Movement	- ( No change )

Prices as at 16:40, 7 Aug 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Already own an Australian ETF? You may already have meaningful exposure to CUV

Clinuvel Pharmaceuticals Limited (CUV) is held across 13 ETFs spanning strategies that include biotechnology exposure . Its weighting in those funds means performance can have an outsized influence - when CUV moves, funds like ISO, SSO, MQAE, DACE and VETH that hold it can move with it.

For more concentrated exposure, ETFs such as ISO (iShares S&P/ASX Small Ordinaries ETF Index Fund) allocate about 0.1% to CUV , while the average exposure across all 13 ETFs that hold it is around 0% .

Top ETF holdings

iShares S&P/ASX Small Ordinaries ETF Index Fund (ISO) ~ 0.1%
SPDR S&P/ASX Small Ordinaries Fund (SSO) ~ 0.1%
Macquarie Core Australian Equity Active ETF (MQAE) ~ 0.1%
Dimensional Australian Core Equity (Managed Fund) (DACE) ~ 0%
Vanguard Ethically Conscious Australian Shares ETF (VETH) ~ 0%

Last updated: ETF data and holdings as at 9 August 2026

Own CUV directly or through an ETF?

How does holding Clinuvel Pharmaceuticals Limited (CUV) shares directly compare to ETFs that include it?

	CUV Direct	ISO ASX	SSO ASX	MQAE ASX	DACE ASX	VETH ASX
Holdings	1 company	198 holdings	201 holdings	215 holdings	470 holdings	234 holdings
CUV Weight	100%	0.1%	0.1%	0.1%	0%	0%
Diversification	Single Stock	Broad	Broad	Broad	Broad	Broad
Annual Cost	Brokerage only	0.55% p.a.	0.5% p.a.	0.03% p.a.	0.28% p.a.	0.16% p.a.
Approx. Yield	-	4.19%	8.94%	2.47%	2.93%	2.74%
Star Ratings	-

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not CUV's direct yield. Annual cost uses each ETF's MER.

CUV Exposure on $10,000 investment

How a $10,000 investment in Clinuvel Pharmaceuticals Limited (CUV) one week ago compares with ETFs that hold it.

Security	Investment type	Current price	7-day price movement	Dollar change	Value today
Clinuvel Pharmaceuticals Limited (CUV)	Direct share	$9.440	4.19%	+$419	$10,419
iShares S&P/ASX Small Ordinaries ETF Index Fund (ISO)	Equity - Australia Small/Mid Cap	$5.210	6.11%	+$611	$10,611
SPDR S&P/ASX Small Ordinaries Fund (SSO)	Equity - Australia Small/Mid Cap	$15.000	6.31%	+$631	$10,631
Macquarie Core Australian Equity Active ETF (MQAE)	Equity - Australia Strategy	$12.500	3.31%	+$331	$10,331
Dimensional Australian Core Equity (Managed Fund) (DACE)	Equity - Australia Strategy	$19.500	3.89%	+$389	$10,389
Vanguard Ethically Conscious Australian Shares ETF (VETH)	Equity - Australia Strategy	$70.800	3.89%	+$389	$10,389

Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.

Clinuvel Pharmaceuticals Limited (CUV) ETFs

13 ETFs hold Clinuvel Pharmaceuticals Limited (CUV).

ETF	CUV Weight	MER	Yield
iShares S&P/ASX Small Ordinaries ETF Index Fund (ISO)	0.1%	0.55%	4.19%
SPDR S&P/ASX Small Ordinaries Fund (SSO)	0.1%	0.5%	8.94%
Macquarie Core Australian Equity Active ETF (MQAE)	0.1%	0.03%	2.47%
Dimensional Australian Core Equity (Managed Fund) (DACE)	0%	0.28%	2.93%
Vanguard Ethically Conscious Australian Shares ETF (VETH)	0%	0.16%	2.74%
Dimensional Australian Value Trust - Active ETF (DAVA)	0%	0.34%	6.47%
Vanguard Australian Shares Index ETF (VAS)	0%	0.07%	2.84%
Global X Australia 300 ETF (A300)	0%	0.03%	2.88%

View all 13 ETFs

Clinuvel Pharmaceuticals Limited (CUV) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield
HFResult	5¢	100%	4 Sep 2025	19 Sep 2025	-	-	-
HFResult	5¢	100%	5 Sep 2024	20 Sep 2024	-	-	-
HFResult	5¢	100%	5 Sep 2023	20 Sep 2023	-	-	-

See all dividends from Clinuvel Pharmaceuticals Limited (CUV) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Clinuvel Pharmaceuticals Limited (CUV) price-sensitive announcements

CUV - Commercial update on vitiligo

CLINUVEL PHARMACEUTICALS LTD provided a commercial update on vitiligo treatments, focusing

Clinuvel Pharmaceuticals Limited (CUV)
30 Jul 2026 | 8:57 AM

CUV - Update - SCENESSE in vitiligo

Clinuvel Pharmaceuticals Limited is advancing its SCENESSE® (afamelanotide) drug in combin

Clinuvel Pharmaceuticals Limited (CUV)
28 Jul 2026 | 8:56 AM

CUV - CLINUVEL strategic reorganisation to refocus on U.S. markets

CLINUVEL Pharmaceuticals Limited announced a strategic reorganisation to refocus its opera

Clinuvel Pharmaceuticals Limited (CUV)
23 Jul 2026 | 9:11 AM

CUV - SCENESSE approved for EPP in Canada

Clinuvel Pharmaceuticals Limited announced that its novel drug SCENESSE® (afamelanotide) h

Clinuvel Pharmaceuticals Limited (CUV)
13 Jul 2026 | 8:34 AM

Clinuvel Pharmaceuticals Limited (CUV) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID	Health Care	$476	Commercial update on vitiligo	30 Jul 2026 8:57AM	$9.590	$9.440	fallen by 1.56%
Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID	Health Care	$476	Update - SCENESSE in vitiligo	28 Jul 2026 8:56AM	$9.810	$9.440	fallen by 3.77%
Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID	Health Care	$476	Notification of cessation of securities - CUV	27 Jul 2026 8:48AM	$10.060	$9.440	fallen by 6.16%
Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID	Health Care	$476	CLINUVEL strategic reorganisation to refocus on U.S. markets	23 Jul 2026 9:11AM	$9.880	$9.440	fallen by 4.45%
Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID	Health Care	$476	CLINUVEL's ADS commences trading on Nasdaq	21 Jul 2026 8:35AM	$10.240	$9.440	fallen by 7.81%
Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID	Health Care	$476	CLINUVEL's ADS to commence trading on Nasdaq	20 Jul 2026 8:33AM	$9.920	$9.440	fallen by 4.84%

CUV Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	PER	DPS	Yield (%)	Franking (%)
2025A	$36.17	$71.80	2.90%	17.60	5.00	0.40%	100.0%
2024A	$35.64	$69.80	18.10%	23.10	5.00	0.30%	100.0%
2023A	$30.60	$59.10	46.70%	33.80	5.00	0.30%	100.0%

CUV Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A
CSL Limited (CSL)	$63,389M	0.1108	-0.1218	0.0167	14.1930	16.1620	15.8962	3.37%	2.75%	2.86%
Clinuvel Pharmaceuticals Limited (CUV)	$473M	0.0287	0.0000	0.0000	13.0501	0.0000	0.0000	0.53%	0.00%	0.00%
Immutep Limited (IMM)	$68M	0.1854	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Mesoblast Limited (MSB)	$2,896M	0.0301	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Telix Pharmaceuticals Limited (TLX)	$5,110M	-1.3893	0.0000	-0.1431	0.0000	247.3684	288.6756	0.00%	0.00%	0.00%

CUV Directors

Name	Position	Start Date
Dr Philippe J Wolgen	Chief Executive Officer, Managing Director	1 Oct 2005
Professor Jeffrey Rosenfeld	Non-Executive Chairman, Non-Executive Director	26 Nov 2019
Mrs Susan (Sue) Smith	Non-Executive Director	23 Sep 2019
Dr Karen Agersborg	Non-Executive Director	29 Jan 2018
Mr Matthew William Pringle	Non-Executive Director	6 Sep 2024
Dr Pearl E Grimes	Non-Executive Director	6 Sep 2024
Mr Guy van Dievoet	Non-Executive Director	6 Sep 2024

Clinuvel Pharmaceuticals Limited (CUV) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
19 Sep 2023	WOLGEN, Philippe	Buy	Direct Shares	1,850	$16.116	$29,813.860
26 Jun 2023	WOLGEN, Philippe	Buy	Direct Shares	1,532	$17.720	$27,147.330
4 Nov 2022	ROSENFELD, Jeffrey	Buy	Indirect Shares	300	$19.440	$5,832.000

See all changes in directors' interest & trades for Clinuvel Pharmaceuticals Limited (CUV) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

CUV Management

Name	Position
Mr P Vaughan	Chief Financial Officer
Mr L Hay	Chief Operating Officer
Dr D Wright	Chief Scientific Officer
Claire Newstead-Sinclair	Company Secretary

CUV Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Clinuvel Pharmaceuticals Limited (CUV). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
3,854,043 (7.69%)	The Bank of New York Mellon Corporation
3,425,222 (6.83%)	Dr Philippe Jacques Wolgen
2,340,824 (4.67%)	Ender 1, LLC and SNP Ventures Group Member

CUV Calendar of Events

Date	Event
25 February 2027	Report (Interim)
28 August 2026	Report (Prelim)
27 August 2026	Report (Annual)
27 August 2026	Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us